Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Disease × obinutuzumab × Clear all

Phase

Status

Terminated 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 9 Lymphoma, Non-Hodgkin 5 Lymphoma, Follicular 5 Lymphoma, Large B-Cell, Diffuse 4 Lymphoma 4 Lymphoma, B-Cell 3 Leukemia 3 Lymphoma, Mantle-Cell 2 Solid Tumors 1 Recurrence 1 Mycosis Fungoides 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, B-Cell, Marginal Zone 1 Leukemia, Myeloid, Acute 1 Indolent Non-Hodgkin's Lymphoma 1 Hodgkin Disease 1 Hereditary Sensory and Autonomic Neuropathies 1 Disease 1 Colorectal Neoplasms 1 Bronchiolitis Obliterans Syndrome 1 Breast Neoplasms 1 B-cell Malignancies 1

Interventions

obinutuzumab 1 ioflupane 1 idelalisib 1 daratumumab 1 alovudine 1 Vindesine 1 Vincristine 1 Rituximab 1 Prednisone 1 Positron Emission Tomography Computed Tomography 1 Mitomycin 1 Magnetic Resonance Spectroscopy 1 Lenalidomide 1 Ga(III)-DOTATOC 1 Doxorubicin 1 Dexamethasone 1 Cyclophosphamide 1 Bleomycin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01659099 2018-03-07

GAINED

The Lymphoma Academic Research Organisation

Phase 3 Terminated

Disease, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡